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1. Preamble
1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for low birth weight as an
adverse event following maternal immunization
The birth weight of an infant is the first weight recorded after
birth, ideally measured within the first hours after birth, before
significant postnatal weight loss has occurred. Low birth weight
(LBW) is defined as a birth weight of less than 2500 g (up to
and including 2499 g), as per the World Health Organization
(WHO) [1]. This definition of LBW has been in existence for many
decades. In 1976, the 29th World Health Assembly agreed on the
currently used definition. Prior to this, the definition of LBW was
‘2500 g or less’. Low birth weight is further categorized into very
low birth weight (VLBW, <1500 g) and extremely low birth
weight (ELBW, <1000 g) [1]. Low birth weight is a result of pre-
term birth (PTB, short gestation <37 completed weeks), intrauter-
ine growth restriction (IUGR, also known as fetal growth
restriction), or both.
The term lowbirthweight refers to an absoluteweight of <2500 g
regardless ofgestational age. Small for gestational age (SGA) refers to
newbornswhosebirthweight is less than the10thpercentile forges-
tational age. This report will focus specifically on birth weight
<2500 g. Further details related to case definitions for PTB [2], IUGR
and SGA are included in separate GAIA reports.
Globally, it is estimated that 15–20% of all births, or >20 million
newborns annually, are low birth weight infants. Low- and middle-
income countries account for a disproportionate burden of LBW;
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over 95% of the world’s LBW infants are born in LMICs. There are
marked global and regional variations in LBW rates. An estimated
6% of infants are born LBW in East Asia and the Pacific, 13% in
Sub-Saharan Africa, and up to 28% in South Asia [3]. Up to half of
all LBW infants are born in south Asia [4]. High-income regions
report lower LBW rates, including 6.9% from UK [5]. Of concern is
the estimated increase in LBW rates in certain middle-income
countries such as Oman, where the LBW rate went from 4% in
1980 to 8.1% in 2000 [6].
One of the major challenges in monitoring the incidence of LBW
is that more than half of infants in the LMICs are not weighed [7].
Population-based survey data often rely on modeled estimates,
with statistical methods to adjust for underreporting and misre-
porting of birth weight. In the context of vaccine safety monitoring,
accurate ascertainment of birth weight in LMICs will continue to
require attention and investment to improve accuracy and report-
ing of this important health indicator.
1.1.1. Why are we concerned about low birth weight?
Low birth weight is a valuable public health indicator of mater-
nal health, nutrition, healthcare delivery, and poverty. Neonates
with low birth weight have a >20 times greater risk of dying than
neonates with birth weight of >2500 g [8,9]. Additionally, low birth
weight is associated with long-term neurologic disability, impaired
language development [10], impaired academic achievement, and
increased risk of chronic diseases including cardiovascular disease
and diabetes. Preterm infants carry additional risk due to immatu-
rity of multiple organ systems, including intracranial hemorrhage,
respiratory distress, sepsis, blindness, and gastrointestinal disor-
ders. Preterm birth is the leading cause of all under-5 child mortal-
ity worldwide [11].
In addition, economic studies in low-income settings have
demonstrated that reducing the burden of low birth weight would
have important cost savings both to the health system and to
households [12].
1.1.2. What leads to low birth weight?
The underlying causes of both PTB and IUGR are multifactorial,
and the biological pathways and preventive strategies for these
two conditions are quite different [13–15]. The exact cause of
PTB may be unknown in many cases, however numerous maternal,
fetal and placental factors may contribute to PTB [13]. Significant
maternal conditions include extra-uterine infection, chorioam-
nionitis, trauma and illness (e.g. pre-eclampsia/eclampsia). Signif-
icant fetal conditions include IUGR, fetal infection, death and
anomalies. Placental pathologic conditions include placental
abruption and placenta praevia [13].
In general, the causes of IUGR can be due to maternal, fetal, and
placental factors. Although the etiologies are different, they often
have the final common pathway of insufficient uterine-placental
perfusion and fetal nutrition.
IUGR can be asymmetrical IUGR (where babies have features of
malnutrition), symmetrical IUGR (hypoplastic small for dates) or
mixed IUGR. Asymmetrical IUGR is the most common (70–80%)
form of IUGR, resulting from an insult (often utero-placental insuf-
ficiency) later in pregnancy, which results in affected babies having
normal length and head circumference (brain sparing), but reduced
weight. Symmetrical IUGR on the other hand arises from an insult
(often genetic, structural or infectious) occurring earlier in preg-
nancy leading to a reduction in all anthropometric parameters in
fetus/newborn [15].
Insufficient perfusion, through abnormal placentation, aberrant
placental vascularization, maternal hypertensive disorders, and
tobacco use, all result in IUGR. Multiple gestation (i.e., twins, tri-
plets) is associated with increased risk of both IUGR and PTB
[16]. Infectious diseases, including intrauterine infections, HIV,
and malaria, result in LBW due to both growth restriction and short
gestation. Multiple maternal characteristics, risk behaviors, and
social determinants are associated with both IUGR and PTB; these
include maternal short stature, maternal malnutrition, low body
mass index, poverty, black race, narrow child spacing, low mater-
nal education, poor antenatal care, substance abuse, and emotional
and physical stress [5,17–19]. How these factors are mediated bio-
logically remains poorly understood.
Preterm birth may be spontaneous or medically-indicated, such
as induction or cesarean section for maternal complications such
as pre-eclampsia. Infectious and inflammatory processes are asso-
ciated with increased risk for PTB, including chorioamnionitis, bac-
terial vaginosis, bacteriuria, and systemic or remote site infection
such as sepsis and periodontal disease.
1.1.3. The importance of short gestation on immune function and
vaccine efficacy
Transplacental antibody transfer is an active process mediated
by Fc receptors in the placental syncytiotrophoblast [20], which
increases from 30 weeks gestation. Small molecular weight parti-
cles (<600 Da) cross the placenta by passive mechanism including
diffusion, however, larger molecular weight particles (>1000 Da)
are transported across the placenta by and active receptor-medi-
ated process [21]. Fetal IgG levels are approximately 50% of mater-
nal antibody level at 32 weeks gestation and rises rapidly through
the third trimester [22]. Preterm newborns have significantly
lower antibody levels than term newborns [22]. LBW term new-
borns have significantly lower antibody concentrations to Herpes
simplex virus type 1, respiratory syncytial virus ad varicella zoster
virus than term newborns with birth weight >2500 g [23].
Maternal antibody levels, receptor density and functionality,
avidity, antigen nature, and gestational age determine the effi-
ciency of placental antibody transfer [24]. Diseases that are highly
prevalent in some areas, such as malaria and human immunodefi-
ciency virus (HIV), are known to cause placental damage, especially
placental malaria [25,26]. Maternal HIV infection has been consis-
tently associated with reduced placental passage of antibodies
against several common viral and bacterial antigens [27,28]. Pla-
cental malaria has been associated with maternal hypergamma-
globulinemia and reduced transfer of antibodies against measles
virus, Clostridium tetani, Streptococcus pneumonia, and varicella-
zoster virus in some studies [20,29–31]. The transfer during preg-
nancy of maternal antibodies to the fetus minimizes deficiencies in
antibody production in the fetus and provides short-term passive
immunity [32], conditioning the success of vaccination in new-
borns [33] which is especially important in preterm and IUGR new-
borns. Multiple comorbidities are associated with both LBW and
immune suppression, such as malnutrition and infection, thereby
further exacerbating diminished immune function in the compro-
mised newborn.
1.1.4. Maternal immunization and birth weight
Maternal infections, including influenza, have been associated
with increased risk of low birth weight newborns [34]. As a corol-
lary, prevention of certain infections during pregnancy might
have a protective effect against LBW. This has been observed in
a maternal immunization trial conducted in Bangladesh [35], in
which the mean birth weight of infants born to mothers who
received an inactivated influenza vaccine during pregnancy was
higher than of infants born to mothers who received a pneumo-
coccal polysaccharide vaccine (3178 g vs. 2978 g, p = 0.02). This
trend has not been observed in other maternal influenza immu-
nization trials [36].
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The field of immunization of pregnant women has highlighted
the importance of knowing background rates of adverse pregnancy
events, including LBW, PTB, SGA, IUGR, stillbirths, and neonatal
death, which can vary markedly between and within regions. The
greatest impact of disease prevention frommaternal immunization
is expected to be observed in LMIC, where the burden of disease is
greatest and access to health care services is most limited. For this
reason, particular attention is being given to advancing maternal
immunization trials in LMICs. Unfortunately, reliable, accurate,
and timely reports of vital statistics and demographic data are
often limited in these settings.
Data Safety Monitoring Boards are established to review clinical
trial data, including regular assessment or review of adverse event
rates in trial participants. Without accurate information on back-
ground rates of low birthweight and other adverse pregnancy out-
comes, it will be impossible to detect an increase in adverse events
following immunization. Development of standardized methods to
collect and report LBW and other essential outcomes will be essen-
tial to advancing maternal immunization programs worldwide.
Birth weight is usually included under demographics of trial
participant infants, and the differences in birth weights between
participants enrolled in active and placebo or control arms of inter-
ventional trials in pregnancy are usually assessed.
The LBW Working Group recommends use of traditional case
definitions of LBW as defined by the World Health Organization.
This report therefore focuses on delineating data quality related
to methods used to estimate birth weight in LMICs, and summa-
rizes some surrogate measurements that are under investigation
to assess birth weight and estimate population-level background
LBW rates.
1.2. Methods for the review of the case definition and guidelines for
data collection, analysis, and presentation for low birth weight in
clinical trial and population settings
Following the process described in the overview paper [21] as
well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Low birth weight Working Groupwas formed
in 2016 and included 16 members of varied backgrounds including
clinical, academic, public health and industry. The composition of
theworking and reference group as well as results of the web-based
survey completed by the reference group with subsequent discus-
sions in the working group can be viewed at: http://www.brighton-
collaboration.org/internet/en/index/working_groups.html.
To guide the decision-making for the guidelines, a literature
search was performed using Medline/PubMed, Embase, ClinicalKey
(ebooks), ScienceDirect (eBooks), eBrary (eBooks) and the
Cochrane Libraries, including the terms: ‘pregnancy, vaccines and
low birth weight’, and restricted to English language publications
since 2005. The search resulted in the identification of 41 refer-
ences. All abstracts were screened for possible reports of Low birth
weight following immunization. Thirty-two articles with poten-
tially relevant material were reviewed in more detail, in order to
identify studies using case definitions or, in their absence, provid-
ing clinical descriptions of the case material. This review resulted
in a detailed summary of 19 articles, including information on
the study type, the vaccine, the diagnostic criteria or case defini-
tion put forth, the time interval since time of immunization, and
any other symptoms. Multiple general medical, pediatric and infec-
tious disease book chapters were also searched.
The definition of low birth weight used was consistent across all
literature reviewed.
A second literature search using the search terms ‘birth weight
and tools’ was performed using Pubmed, to identify other mea-
surements used as proxies for birth weight. The search, unre-
stricted for language and year of publication, identified in 235
results. Titles were screened and 10 articles were identified for fur-
ther review.
1.3. Rationale for selected decisions about the case definition of low
birth weight as an adverse event following maternal immunization
1.3.1. The term low birth weight
‘Low birth weight’ (LBW) has been defined as first weight
recorded within hours of birth of <2500 g. Very low birth weight
(VLBW) is accepted as <1500 g and extremely low birth weight
(ELBW) is <1000 g [1].
Within the definition context, however, the three diagnostic
levels must not be misunderstood as reflecting different grades
of clinical severity. They instead reflect diagnostic certainty.
The levels of certainty have been formulated such that the Level
1 definition is highly specific for the condition. Two additional
diagnostic levels have been included in the definition, offering a
stepwise loss of precision and accuracy from Level One down to
Level Three, while retaining an approach to expand utilization of
available data. In this way it is hoped that information on low birth
weight can be captured more broadly at the population level.
1.3.2. Timing of birth weight assessment
The birth weight is described as the first weight measured,
however, in settings with low rates of facility-based deliveries, a
newborn may not be assessed by a health care worker until several
days old. Birth weight should be assessed within hours of birth,
prior to significant weight loss [37]. Term neonates lose between
3.5% and 6.6% of their birth weight within the first 2.5–2.7 days
of life. Exclusively breastfed neonates have a greater weight loss
(Median 6.6%, 95%CI 6.3–6.9%) than formula-fed (Median 3.5%,
95%CI 3.0–3.9%) or mixed fed (5.9%, 95%CI 4.8–6.9%) neonates
respectively, and take longer to regain their birth weight (8.3 vs.
6.5 vs. 7.9 days) [37].
The LBW working group decided to restrict ‘birth weight’ to a
weight measured in the first 48 h of life. In the absence of a weight
measured within the first 48 h of life, a weight measured during
the first week of life, could be classified as an ‘early neonatal
weight’ but not ‘birth weight’.
In a clinical trial scenario, measurement of weight within first
48 h of life should be achievable, as the clinical trial would procure
adequate equipment, employ and train staff to assess birth weight
in a timely manner, and enroll participants who reside in areas
which are relatively easily accessed by trial or health care staff.
Many newborns globally are not weighed within hours of birth,
mainly due to difficulty in accessing health care personnel, facili-
ties, and essential equipment. Specific time frames for onset of
symptoms following immunization are not included for the follow-
ing main reasons:
We postulate that a definition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
(e.g. low birth weight) independent from the exposure (e.g. immu-
nizations). Therefore, to avoid selection bias, a restrictive time
interval from immunization to birth of a LBW newborn should
not be an integral part of such a definition. Instead, where feasible,
details of this interval should be assessed and reported as
described in the data collection guidelines.
Further, measurement of birth weight often occurs outside the
controlled setting of a clinical trial or hospital. In some settings it
may be impossible to obtain a clear timeline of the assessment of
a birth weight, particularly in less developed or rural settings. In
order to avoid selecting against such cases, the Brighton Collabora-
tion case definition avoids setting arbitrary time frames. The time
between delivery and measurement of birth weight should be
recorded and accounted for in the analysis.
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1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper [38], the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial, i.e. data collection, analysis
and presentation. Neither case definition nor guidelines are
intended to guide or establish criteria for management of ill
infants, children, or adults. Both were developed to improve
standardization of case definitions and data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of low birth weight3
Level 1 of diagnostic certainty
Newborn infant weighed within 24 h of birth AND
Use electronic scale which is graduated to 10 g AND
Scale is calibrated at least once a year AND
Scale placed on level, hard surface AND
Scale tared to zero grams AND
Weight recorded as <2500 g OR
Birth weight recorded as <2500 g AND
Birth weight assessed as per health care facility’s
standard operating procedure, which fulfills criteria
1 to 5 of LOC1
Level 2 of diagnostic certainty
Newborn infant weighed within 24 h of birth AND
Scale (electronic/spring) is graduated to at least 50 g AND
Scale is calibrated at least once a year, or more often if
moved
AND
Scale tared to zero grams or 0.00 kg AND
Weight recorded as <2500 g OR
Birth weight recorded as <2500 g AND
Birth weight assessed as per health care facility’s
standard operating procedure, which fulfills criteria
1 to 4 of LOC2
Scale used: could be electronic or spring scale, including color-
coded scale.
Level 3 of diagnostic certainty
Newborn infant weighed on day 1 or 2 of life (first 48 h
of life)
AND
Weight measured using dial/spring/color-coded scale AND
Weight assessed as <2500 g
Level 4 of diagnostic certainty
Newborn infant ‘weight’ assessed on day 1 or 2 of life
(first 48 h of life)
AND
Proxy measure of birth weight used AND
Weight CATEGORY assessed as <2500 g
In many settings, including high-income countries, birth weight is
assessed by a health care providerwho is attendant during/soon after
delivery, and not the vaccine trialist/researcher. The details of time of
birth weight assessment, and details of scale used and calibration
details are usually not recorded in newborn assessment medical
notes.
The newborn weight assessment is presumed to be assessed
accurately as per health care center’s standard operating proce-
dures. In many instances, trialists need to rely on the attending
medical staff at health care facility for birth weight assessment.
Strengthening training and oversight of birth weight measurement
would be expected to strengthen data both in clinical trials and
post-marketing surveillance.
2.1. Other tools under investigation to estimate birth weight in
individuals and populations
Up to 60 million infants are born at home annually [39], and up
to 48% of infants worldwide are not weighed at birth [3]. Lack of
access to health care facilities or health care workers hampers
accurate assessment of low birth weight rates in many regions.
In order to identify small newborns, who could be preterm, IUGR,
or both, who require additional care, inexpensive tools are required
which can be utilized in the field.
The lack of data available has encouraged the development of a
mathematical model to calculate the expected number of adverse
events, including neonatal and maternal deaths, SGA, preterm birth
and major congenital malformations [40].
Several anthropometric measurements, including chest circum-
ference, foot length and mid-upper arm circumference, have been
assessed as proxies for birth weight [41–44]. Table 1 summarizes
these tools and their validity for identifying low birth weight new-
borns. These tools at this point are considered investigational and
have been included in level 4 definition only, which indicates that
evidence is inadequate to meet the definition, however, may be
useful for population background LBW estimates.
In addition to these measurements, other tools are utilized in
some communities to assess birth weight, including difference
between adult weight with and without newborn in arms (see
Fig. 1).
3. Guidelines for data collection, analysis and presentation of
low birth weight
It was the consensus of the Brighton Collaboration Working
Group for Low birth weight to recommend the following guidelines
to enable meaningful and standardized collection, analysis, and
presentation of information about low birth weight. However,
implementation of all guidelines might not be possible in all set-
tings. The availability and quality of information may vary depend-
ing upon resources, geographical region, and whether the source of
information is a prospective clinical trial, epidemiological study,
post-marketing surveillance, or an individual report. Also, as
explained in more detail in the overview paper [38], these guideli-
nes have been developed by this working group for guidance only,
and are not to be considered a mandatory requirement for data col-
lection, analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collection
of data on availability following immunization to allow for compara-
bility of data, and are recommended as an addition to data collected
for the specific study question and setting. The guidelines are not
intended to guide the primary reporting of low birth weight to a
surveillance system or study monitor. Investigators developing a
3 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.
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data collection tool based on these data collection guidelines also
need to refer to the criteria in the case definition, which are not
repeated in these guidelines.
Guidelines numbers below have been developed to address data
elements for the collection of adverse event information as specified
in general drug safety guidelines by the International Conference on
Harmonization of Technical Requirements for Registration of Phar-
maceuticals for Human Use [49], and the form for reporting of drug
adverse events by the Council for International Organizations of
Medical Sciences [50]. These data elements include an identifiable
reporter and patient, one or more prior immunizations, and a
detailed description of the adverse event, in this case, of low birth
weight following immunization. The additional guidelines have
been developed as guidance for the collection of additional informa-
tion to allow for a more comprehensive understanding of low birth
weight following maternal immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting4 and/or
diagnosing low birth weight as specified by country-specific
data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., healthcare provider, immunizer,
community health worker, family member [indicate rela-
tionship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants, as
appropriate, the following information should be recorded:
(5) Case/study participant identifiers for mother and newborn
(e.g. first name initial followed by last name initial) or
code (i.e. hospital identifier or in accordance with coun-
try-specific data protection laws). Each newborn should
have a unique identifier, ideally linked to mother’s identi-
fier (e.g. participant code could be same for mother and
baby(ies), with an added prefix/suffix to identify mother/
baby).
(6) Maternal date of birth, or if not available, maternal age.
(7) For each infant: Date and time of delivery, single or multiple,
live birth vs. fetal death (fresh or macerated), estimated ges-
tational age, method of determination of gestational age
(LMP, fundal height, first trimester ultrasound) and birth
weight.
 For collection of birth weight, ideally record timeline of
weight measurement (e.g. time of delivery to time of
weight), type of scale used (e.g. surface-mounted spring)
and place where birth weight was measured (e.g. health
care facility, mobile health worker visiting home).
3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants, as appropriate, the following information
should be recorded:
(8) Maternal past medical history, including hospitalizations,
gravidity and parity, underlying diseases/disorders; compli-
cations of pregnancy, labor, or delivery; pre-immunization
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4 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.
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signs and symptoms including identification of indicators
for, or the absence of, a history of allergy to vaccines, vaccine
components or medications; food allergy; allergic rhinitis;
eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect. (E.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of low birth weight after a previous maternal
immunization.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of maternal immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL), vaccine diluent (compo-
sition and lot number) and number of dose if part of a series
of immunizations against the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Severity of Low birth weight (LBW, VLBW or ELBW), and if
there was medical confirmation of the LBW (i.e. patient seen
by physician/other health care worker).
(18) Date/time of observation,5 and diagnosis.6
(19) Concurrent signs, symptoms, and diseases, including
prematurity.
(20) Measurement/testing.
 Values and units of routinely measured parameters
(grams for birth weight);
 Method of measurement (e.g. type of scale.);
A Surface -mounted dial baby scale
B Spring scale with graduated dial C Low cost, color coded, hand held spring scale 45
Fig. 1. Tools used to measure birth weight (See above-mentioned references for further information.).
5 The date and/or time of observation is defined as the time post immunization,
when the Low birth weight was recorded.
6 The date of diagnosis of an episode is the day post immunization when the event
met the case definition at any level.
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 Weight should be recorded with minimal or ideally no
clothing;
(21) Objective clinical evidence supporting classification of the
event as ‘‘serious”.7
(22) Exposures other than the immunization 24 h before and
after immunization (e.g. infection, environmental) consid-
ered potentially relevant to the reported event.8
3.1.5. Miscellaneous/general
(23) The duration of surveillance for low birth weight should be
from 0 to 48 h of life. Any weight measured after 48 h of
age should not be considered a ‘birth weight’.9
(24) Methods of data collection should be consistent within and
between study groups, if applicable.10
(25) Investigators of patients with low birth weight should pro-
vide guidance to reporters to optimize the quality and com-
pleteness of information provided.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on low birth weight to allow for comparability of
data, and are recommended as an addition to data analyzed for
the specific study question and setting.
(26) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories
Event meets case definition
(1) Level 1: Criteria as specified in the Low birth weight case
definition
(2) Level 2: Criteria as specified in the Low birth weight case
definition
(3) Level 3: Criteria as specified in the Low birth weight case
definition
Event does not meet case definition
Additional categories for analysis
(4) Reported Low birth weight with insufficient evidence to
meet the case definition.7
(5) Birth weight not assessed, therefore data unavailable.
(27) The interval between immunization and reported Low birth
weight could be defined as the date/time of immunization to
the date/time of assessment4 of birth weight. If few cases are
reported, the concrete time course could be analyzed for
each; for a large number of cases, data can be analyzed in
the following increments.
(28) If birth weight is assessed by more than one method, the
value recorded which fulfills the highest level of certainty
should be used as the basis for analysis.
(29) The distribution of birth weight data could be analyzed in
predefined increments (e.g. LBW < 2500 g, VLBW < 1500 g,
ELBW < 1000 g). Increments specified above should be used.
When only a small number of cases are presented, the
respective values can be presented individually.
(30) Data on Low birth weight obtained from participants whose
mothers received a vaccine should be compared with those
obtained from an appropriately selected and documented
control group to assess background rates of LBW in non-
exposed populations, and should be analyzed by study arm
and dose where possible, e.g. in prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on Low birth weight following
immunization to allow for comparability of data, and are recom-
mended as an addition to data presented for the specific study
question and setting. Additionally, it is recommended to refer to
existing general guidelines for the presentation and publication
of randomized controlled trials, systematic reviews, and meta-
analyses of observational studies in epidemiology (e.g. statements
of Consolidated Standards of Reporting Trials (CONSORT) [51], of
Improving the quality of reports of meta-analyses of randomized
controlled trials (QUORUM) [52], and of meta-analysis Of Observa-
tional Studies in Epidemiology (MOOSE) [53], respectively).
(31) All reported events of Low birth weight should be presented
according to the categories listed in guideline 31.
(32) Data on Low birth weight events should be presented in
accordance with data collection guidelines 1–25 and data
analysis guidelines 26–30.
(33) Data should be presented as rates with a numerator and
denominator (n/N) (and not only in percentages), with con-
fidence intervals around the point estimates.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(34) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(35) If the distribution of birth weight data is skewed, median
and range are usually the more appropriate statistical
descriptors than a mean. However, the mean and standard
deviation should also be provided.
7 An AEFI is defined as serious by international standards if it meets one or more of
the following criteria: (1) it results in death, (2) is life-threatening, (3) it requires
inpatient hospitalization or results in prolongation of existing hospitalization, (4)
results in persistent or significant disability/incapacity, (5) is a congenital anomaly/
birth defect, (6) is a medically important event or reaction.
8 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of the
definition is met, and there is evidence that the criteria of the next higher level of
diagnostic certainty are met, the event should be classified in the next category. This
approach should be continued until the highest level of diagnostic certainty for a
given event could be determined. Major criteria can be used to satisfy the
requirement of minor criteria. If the lowest level of the case definition is not met, it
should be ruled out that any of the higher levels of diagnostic certainty are met and
the event should be classified in additional categories four or five.
9 If the evidence available for an event is insufficient because information is
missing, such an event should be categorized as ‘‘Reported Low birth weight with
insufficient evidence to meet the case definition”.
10 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of Low birth weight”.
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(36) Any publication of data on Low birth weight should include
a detailed description of the methods used for data collec-
tion and analysis as possible. It is essential to specify:
 The study design;
 The method, frequency and duration of monitoring for
Low birth weight;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset4 and/or the date of first obser-
vation5 and/or the date of diagnosis6 was used for analy-
sis; and
 Use of this case definition for Low birth weight, in the
abstract or methods section of a publication.11
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